  FLASH radiotherapy (FLASH-RT) has shown the potential to spare normal tissue
while seemingly maintaining the effectiveness of conventional radiotherapy
(CONV-RT). It has been suggested that the protective effect arises from the
radiolytic oxygen depletion (ROD) caused by FLASH-RT, but it is not entirely
clear why this protective effect is not observed in tumors. Iso-effectiveness
has been experimentally observed in time-volume curves of preclinical tumors
irradiated with FLASH and conventional radiotherapy, but it may not translate
to clinical trials, where tumor control probability (TCP) is typically the
investigated endpoint.
  In this work, we used mathematical models to investigate the
iso-effectiveness of FLASH-RT/CONV-RT on tumors, focusing on the role of ROD.
We used a spatiotemporal reaction-diffusion model, including ROD, to simulate
tumor oxygenation. From those oxygen distributions we obtained surviving
fractions (SFs), using the linear-quadratic model with oxygen enhancement
ratios (OER). We then used the calculated SFs to describe the evolution of
preclinical tumor volumes through a mathematical model of tumor response. We
also calculated TCPs using the Poisson-LQ approach.
  Our study suggests that ROD causes differences in SF between FLASH-RT and
CONV-RT, especially in low $\alpha$/$\beta$ and poorly oxygenated cells. These
changes do not lead to significant differences in the evolution of preclinical
tumors. However, when extrapolating this effect to TCP curves, we observed
important differences between both techniques (TCP is lower in FLASH-RT).
Nonetheless, it cannot be discarded that other effects not modeled in this work
could contribute to tumor control and maintain the iso-effectiveness of
FLASH-RT.
